Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
REGN4659 is a human monoclonal antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response and decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 3824).
|DrugClasses||CTLA4 Antibody 21 Immune Checkpoint Inhibitor 135|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Cemiplimab + REGN4659||Cemiplimab REGN4659||0||1|